R
RenovoRx, Inc. (RNXT)
NCM – Real vaqt narxi. Valyuta: USD
0.94
+0.01 (1.47%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
0.95
+0.01 (1.13%)
Bozordan keyin: Jun 26, 2026, 5:41 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.94
+0.01 (1.47%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
0.95
+0.01 (1.13%)
Bozordan keyin: Jun 26, 2026, 5:41 PM EDT
RenovoRx, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saraton kasalligiga chalingan bemorlarning davolash natijalarini yaxshilash uchun maqsadli kombinatsiyalangan terapiyalarni ishlab chiqish bilan shug'ullanadi. Uning asosiy mahsulot nomzodi kimyoterapiya gemcitabine bo'lib, u RenovoCath orqali taqdim etiladi va mahalliy rivojlangan oshqozon osti bezi saratonini davolash uchun III bosqich klinik sinovlarida. Kompaniya 2009 yilda tashkil etilgan va uning shtab-kvartirasi Mountain View, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ramtin Agah M.D. | Founder, Executive Chairman & Chief Medical Officer |
| Mr. Mark Voll | CFO & Principal Accounting Officer |
| Mr. Robert Strasser | Vice President of Operations and R&D |
| Mr. Ronald B. Kocak CPA, CGMA | VP of Finance & Controller |
| Mr. Ryan Witt | Senior VP and Head of Corporate Strategy & Partnerships |
| Mr. Shaun R. Bagai | CEO, Secretary & Director |
| Ms. Leesa Gentry | Chief Clinical Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-15 | 10-K/A | rnxt-20251231.htm |
| 2026-05-14 | 8-K | rnxt-20260514.htm |
| 2026-05-14 | 10-Q | rnxt-20260331.htm |
| 2026-04-30 | DEF 14A | formdef14a.htm |
| 2026-04-23 | CORRESP | filename1.htm |
| 2026-04-16 | S-3 | forms-3.htm |
| 2026-04-09 | D | |
| 2026-03-31 | S-8 | forms-8.htm |
| 2026-03-30 | 8-K | form8-k.htm |
| 2026-03-30 | 10-K | rnxt-20251231.htm |